SCYNEXIS, Inc.
Mar 7, 2017

SCYNEXIS, Inc. to Present at the 29th Annual ROTH Conference

JERSEY CITY, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the 29th Annual ROTH Conference at the Ritz Carlton Laguna Niguel in Dana Point on Tuesday, March 14, 2017 at 5:30 p.m. PT.

A live webcast will be available on the Investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

About SCYNEXIS
SCYNEXIS is a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.

CONTACT:

Media Relations
Cammy Duong
MacDougall Biomedical Communications
Tel: 781.591.3443
cduong@macbiocom.com

Investor Relations
Susan Kim
Argot Partners
Tel: 212-203-4433
susan@argotpartners.com